Cargando…

Nivolumab-induced diabetes mellitus—a case report with literature review of the treatment options

BACKGROUND: Immune checkpoint inhibitor (ICI) treatment has become important for treating various cancer types, including metastatic renal cell carcinoma. However, ICI treatment can lead to endocrine immune-related adverse events (irAEs) by overstimulating the patient’s immune system. Here, we repor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Daetwyler, Eveline, Zippelius, Alfred, Danioth, Simona, Donath, Marc Y., Gut, Lara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640970/ https://www.ncbi.nlm.nih.gov/pubmed/37965350 http://dx.doi.org/10.3389/fimmu.2023.1248919

Ejemplares similares

Pembrolizumab-induced optic neuropathy – a case report
por: Daetwyler, Eveline, et al.
Publicado: (2023)

Tertiary Lymphoid Structures as a Predictive Biomarker of Response to Cancer Immunotherapies
por: Trüb, Marta, et al.
Publicado: (2021)

Multiorgan Failure From Nivolumab and Ipilimumab: A Case Report and Literature Review
por: Brazel, Danielle, et al.
Publicado: (2023)

Modulation of APC Function and Anti-Tumor Immunity by Anti-Cancer Drugs
por: Martin, Kea, et al.
Publicado: (2015)

Immune checkpoint inhibitor-induced diabetes mellitus with nivolumab
por: Zand Irani, Anis, et al.
Publicado: (2023)

Nivolumab plus ipilimumab induced endocrinopathy and acute interstitial nephritis in metastatic sarcomatoid renal-cell carcinoma: A case report and review of literature
por: Hino, Christopher, et al.
Publicado: (2022)

Fatal Necrotizing Encephalopathy after Treatment with Nivolumab for Squamous Non-Small Cell Lung Cancer: Case Report and Review of the Literature
por: Leitinger, Markus, et al.
Publicado: (2018)

Changes of peripheral T cell subsets in melanoma patients with immune-related adverse events
por: Müller, Benjamin, et al.
Publicado: (2023)

Immune checkpoint inhibitors-related pancreatitis with fulminant type 1 diabetes mellitus: case report and literature review
por: Fang, Wei, et al.
Publicado: (2023)

The Latest Option: Nivolumab and Relatlimab in Advanced Melanoma
por: Albrecht, Lea Jessica, et al.
Publicado: (2023)

Clinical and pathological factors and outcome of central nervous system metastasis in breast cancer
por: Dettwiler, Dimitri, et al.
Publicado: (2023)

Case Report: Thrombotic-Thrombocytopenic Purpura Following Ipilimumab and Nivolumab Combination Immunotherapy for Metastatic Melanoma
por: Mullally, W. J., et al.
Publicado: (2022)

Case Report: Maintenance Nivolumab in Complete Responder After Multimodality Therapy in Metastatic Pancreatic Adenocarcinoma
por: Yang, Shih-Hung, et al.
Publicado: (2022)

Association of immune-related adverse events induced by nivolumab with a battery of autoantibodies
por: Les, Iñigo, et al.
Publicado: (2021)

Pemphigus vulgaris as an immune-related adverse event in recurrent metastatic esophageal squamous cell carcinoma treated with ipilimumab plus nivolumab: a case report and literature review
por: Nakamura, Hajime, et al.
Publicado: (2023)

Gestational Diabetes Mellitus Is Associated with Altered Neutrophil Activity
por: Stoikou, Maria, et al.
Publicado: (2017)

Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer
por: Ottonello, Selene, et al.
Publicado: (2020)

Thyroid Storm and Type 1 Diabetes Mellitus Induced by Combined Ipilimumab and Nivolumab Immunotherapy: A Case Report
por: Ramburuth, Vivek, et al.
Publicado: (2023)

Chemokines in Gestational Diabetes Mellitus
por: Liu, Hongying, et al.
Publicado: (2022)

Nivolumab-induced autoimmune diabetes mellitus and hypothyroidism in a patient with rectal neuroendocrine tumor
por: Haque, Waqas, et al.
Publicado: (2020)

Case report: Heterogenous SMARCA4-deficient thoracic non-small cell lung carcinoma with various responses to nivolumab
por: Lin, Yun-Tzu, et al.
Publicado: (2023)

Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer
por: Godwin, James Luke, et al.
Publicado: (2017)

Early Response Assessment in Advanced Stage Melanoma Treated with Combination Ipilimumab/Nivolumab
por: Ma, Vincent T., et al.
Publicado: (2022)

Case Report: Complete Remission of a Patient With Metastatic Gastric Cancer Treated With Nivolumab Combined With Chemotherapy After Palliative Surgery
por: Dai, Peilin, et al.
Publicado: (2022)

Chemokines in Type 1 Diabetes Mellitus
por: Pan, Xiongfeng, et al.
Publicado: (2022)

New-Onset Type 1 Diabetes Mellitus After Treatment With Nivolumab for Melanoma
por: Baroud, Sarah, et al.
Publicado: (2021)

Diabetic ketoacidosis induced by nivolumab in invasive mucinous adenocarcinoma of the lung: a case report and review of the literature
por: Yan, Juan, et al.
Publicado: (2022)

Nivolumab-Induced Alopecia Areata: A Case Report and Literature Review
por: Kim, Ki-Hun, et al.
Publicado: (2021)

High incidence and early onset of nivolumab-induced pneumonitis: four case reports and literature review
por: Koyama, N., et al.
Publicado: (2018)

Emerging treatment options for the management of Hodgkin’s lymphoma: clinical utility of nivolumab
por: Bond, David A, et al.
Publicado: (2017)

Maintenance therapy of low-dose nivolumab, S-1, and leucovorin in metastatic pancreatic adenocarcinoma with a germline mutation of MSH6: A case report
por: Peng, Shang-Hsuan, et al.
Publicado: (2022)

PD-L1(+) neutrophils as novel biomarkers for stage IV melanoma patients treated with nivolumab
por: Cristinziano, Leonardo, et al.
Publicado: (2022)

Phase 1 pilot study of RRx-001 + nivolumab in patients with advanced metastatic cancer (PRIMETIME)
por: Reid, Tony, et al.
Publicado: (2023)

Combination therapy of ipilimumab and nivolumab induced thyroid storm in a patient with Hashimoto’s disease and diabetes mellitus: a case report
por: Yonezaki, Kazuko, et al.
Publicado: (2018)

Immunobiology of Gestational Diabetes Mellitus in Post-Medawar Era
por: Sharma, Surendra, et al.
Publicado: (2022)

Pericardial effusion under nivolumab: case-reports and review of the literature
por: Anastasia, Saade, et al.
Publicado: (2019)

SUN-LB036 Diabetic Ketoacidosis: A Rare Side Effect of Nivolumab Induced Insulin Dependent Diabetes Mellitus
por: Abid, Haisam, et al.
Publicado: (2019)

Multi-Scale Spatial Analysis of the Tumor Microenvironment Reveals Features of Cabozantinib and Nivolumab Efficacy in Hepatocellular Carcinoma
por: Mi, Haoyang, et al.
Publicado: (2022)

Reduction of T Lymphoma Cells and Immunological Invigoration in a Patient Concurrently Affected by Melanoma and Sezary Syndrome Treated With Nivolumab
por: Narducci, Maria Grazia, et al.
Publicado: (2020)

Nivolumab adjuvant therapy for esophageal cancer: a review based on subgroup analysis of CheckMate 577 trial
por: Lin, Yan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_uelor2d48o77jim621t4oa7o4g